VERU INC. Other Significant Noncash Transaction, Value of Consideration Given
VERU INC. (VERU) reported Other Significant Noncash Transaction, Value of Consideration Given of $680.94 thousand for the 12-month period ending 2020-09-30, per its 10-K filed 2020-12-10.
Discontinued › Cash Flow › Operating Activities
us-gaap:OtherSignificantNoncashTransactionValueOfConsiderationGiven1 · last filed 2020-12-10
- VERU INC. other significant noncash transaction, value of consideration given for the quarter ending 2020-09-30 was $0.00.
- VERU INC. other significant noncash transaction, value of consideration given for fiscal 2020 was $680.94K.
| Period end | Other Significant Noncash Transaction, Value of Consideration Given 3 month | Other Significant Noncash Transaction, Value of Consideration Given 9 month | Other Significant Noncash Transaction, Value of Consideration Given 12 month |
|---|---|---|---|
| 2020-09-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-12-10 | $680.94K 10-K · filed 2020-12-10 | |
| 2020-06-30 | $680.94K 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |